LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx ...

RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug ...

A new study led by researchers at Baylor College of Medicine found that the use of a take-home electrical stimulation device improved muscle perfusion, the rate at which oxygen is delivered to muscles ...

Data supports the novel Trans-Arterial Micro-Perfusion (TAMP TM) therapy platform for targeted chemotherapy delivery for the potential to minimize a therapy’s toxicities versus systemic intravenous ...

First commercially available cell culture solution for HEK293 cells and perfusion -– optimized for high cell density (HCD), intensified processes and perfusion cultures Additional capabilities for ...

A Chinese research team has used a gene-edited pig liver in an extracorporeal perfusion therapy to treat a patient with acute liver failure. The process saved the patient's life and significantly ...

FUJIFILM Biosciences, announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company’s portfolio of gene therapy application solutions, BalanCD HEK293 ...

FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A.